The biotech scorecard for Q3 quarter: 15 stock-moving occasions to look at

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Road, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and creator of the e-newsletter Adam’s Biotech Scorecard. You possibly can attain Adam on Sign at stataf.54.

Right here is STAT’s biotech scorecard, our common ledger of stock-moving biotech occasions, for the third quarter:

Amylyx Prescribed drugs: Outcomes from the Section 3 LUCIDITY examine of avexitide in post-bariatric hypoglycemia, a uncommon metabolic situation that causes extreme drops in blood sugar. 

Biogen: In Could, the corporate introduced outcomes from a mid-stage medical trial investigating a remedy for Alzheimer’s illness referred to as diranersen that targets the protein tau. Detailed information from the examine will likely be offered on July 14 on the Alzheimer’s Affiliation Worldwide Convention.